| Literature DB >> 35287597 |
Sally Yaacoub1,2, Claudia Truppa3, Thomas Ingemann Pedersen4, Hicham Abdo5, Rodolfo Rossi4.
Abstract
BACKGROUND: A substantial body of evidence has recently emphasized the risks associated with antibiotic resistance (ABR) in conflicts in the Middle East. War-related, and more specifically weapon-related wounds can be an important breeding ground for multidrug resistant (MDR) organisms. However, the majority of available evidence comes from the military literature focused on risks and patterns of ABR in infections from combat-related injuries among military personnel. The overall aim of this study is to contribute to the scarce existing evidence on the burden of ABR among patients, including civilians with war-related wounds in the Middle East, in order to help inform the revision of empirical antibiotic prophylaxis and treatment protocols adopted in these settings. The primary objectives of this study are to: 1) describe the microbiology and the corresponding resistance profiles of the clinically relevant bacteria most commonly isolated from skin, soft tissue and bone biopsies in patients admitted to the WTTC; and 2) describe the association of the identified bacteria and corresponding resistance profiles with sociodemographic and specimen characteristics.Entities:
Keywords: Bacterial drug resistance; Multidrug-resistance; Refugees; Vulnerable populations; War wounds; Wound infection
Mesh:
Year: 2022 PMID: 35287597 PMCID: PMC8922823 DOI: 10.1186/s12879-022-07253-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of the identified isolates from the specimens of bone and skin and soft tissues of patients with war-related injuries (N = 348)
| Characteristic | Enterobacterales (N = 99) | Other bacteria† | p-value‡ | Total | ||
|---|---|---|---|---|---|---|
| Sociodemographic | ||||||
| Age** [IQR], y | 33 [25–43] | 33 [25–48] | 35 [26.5–45.3] | 41.5 [33.3–50.3] | 0.049 | 34.5 [26–44] |
| Sex | 0.702 | |||||
| Male | 144 (50.5) | 80 (28.1) | 36 (12.6) | 25 (8.8) | 285 (81.9) | |
| Female | 27 (42.9) | 19 (30.2) | 10 (15.9) | 7 (11.1) | 63 (18.1) | |
| Nationality | 0.400 | |||||
| Syria | 138 (51.1) | 71 (26.3) | 37 (13.7) | 24 (8.9) | 270 (77.6) | |
| Iraq | 13 (48.1) | 9 (33.3) | 4 (14.8) | 1 (3.7) | 27 (7.8) | |
| Lebanon | 11 (50.0) | 6 (27.3) | 3 (13.6) | 2 (9.1) | 22 (6.3) | |
| Palestine | 5 (27.8) | 7 (38.9) | 2 (11.1) | 4 (22.2) | 18 (5.2) | |
| Yemen | 4 (36.4) | 6 (54.5) | 0 (0.0) | 1 (9.1) | 11 (3.2) | |
| Specimen | ||||||
| Site | 0.844 | |||||
| SST | 101 (51.0) | 55 (27.8) | 24 (12.1) | 18 (9.1) | 198 (56.9) | |
| Bone | 70 (46.7) | 44 (29.3) | 22 (14.7) | 14 (9.3) | 150 (43.1) | |
| Year of collection | 0.498 | |||||
| 2016 | 36 (41.9) | 32 (37.2) | 9 (10.5) | 9 (10.5) | 86 (24.7) | |
| 2017 | 51 (52.0) | 25 (25.5) | 16 (16.3) | 6 (6.1) | 98 (28.2) | |
| 2018 | 40 (49.4) | 24 (29.6) | 9 (11.1) | 8 (9.9) | 81 (23.3) | |
| 2019 | 44 (53.0) | 18 (21.7) | 12 (14.5) | 9 (10.8) | 83 (23.8) | |
IQR Interquartile range, SST skin and soft tissue, y years
*The percentages are calculated based on the number of isolates reported under ‘Total’ per row
**Continuous variables are presented as medians. The Kruskal–Wallis test was used for the relevant statistical analysis
†Other bacteria include coagulase-negative staphylococci (n = 7), Acinetobacter baumannii (n = 7), Enterococcus species (n = 11), and Streptococcus group A (n = 7)
‡The Chi-square test or the Fisher’s exact test (when the expected cell counts are < 5) were used for the relevant statistical analysis, except for the variable age
§The percentages are calculated based on the total N = 348
Factors associated with multi-drug resistant isolates identified from the specimens of bone and skin and soft tissues of patients with war-related injuries
| Factor | MDR | Unadjusted OR (95% CI)* | p-value** | Adjusted OR (95% CI)† | p-value** |
|---|---|---|---|---|---|
| Sociodemographics | |||||
| Age | – | 0.993 (0.978, 1.009) | 0.389 | 0.998 (0.980, 1.016) | 0.786 |
| Sex | |||||
| Male | 156 (83.9) | 1 | 0.410 | 1 | 0.480 |
| Female | 30 (16.1) | 0.789 (0.449, 1.386) | 0.791 (0.412, 1.518) | ||
| Nationality | |||||
| Syria | 135 (72.6) | 1 | 0.006 | 1 | 0.026 |
| Iraq | 23 (12.4) | 5.28 (1.777, 15.699) | 5.899 (1.848, 18.835) | ||
| Lebanon | 9 (4.8) | 0.636 (0.263, 1.539) | 0.624 (0.228, 1.712) | ||
| Palestine | 10 (5.4) | 1.837 (0.611, 5.523) | 1.597 (0.448, 5.698) | ||
| Yemen | 9 (4.8) | 4.133 (0.876, 19.5) | 1.964 (0.364, 10.612) | ||
| Specimen | |||||
| Bacteria | |||||
| | 83 (44.6) | 1 | < 0.001 | 1 | < 0.001 |
| Enterobacterales | 83 (44.6) | 5.5 (2.978, 10.15) | 5.662 (2.981, 10.755) | ||
| | 14 (7.6) | 0.464 (0.231, 0.93) | 0.427 (0.204, 0.893) | ||
| | 3 (1.6) | 0.795 (0.173, 3.66) | 0.801 (0.163, 3.941) | ||
| Enterococci | 3 (1.6) | 0.398 (0.102, 1.55) | 0.361 (0.085, 1.532) | ||
| Site | |||||
| SST | 97 (52.2) | 1 | 0.051 | 1 | 0.071 |
| Bone | 89 (47.8) | 1.551 (0.999, 2.410) | 1.590 (0.961, 2.632) | ||
| Year of collection | |||||
| 2016 | 46 (24.7) | 1 | 0.432 | 1 | 0.723 |
| 2017 | 56 (30.1) | 1.187 (0.659, 2.319) | 1.181 (0.59, 2.367) | ||
| 2018 | 47 (25.3) | 1.328 (0.710, 2.484) | 1.18 (0.564, 2.467) | ||
| 2019 | 37 (19.9) | 0.804 (0.433, 1.495) | 0.819 (0.400, 1.678) | ||
CI confidence interval, MDR multi-drug resistant, OR odds ratio, SST skin and soft tissue
*Univariate logistic regression models were conducted
**p-value from Likelihood Ratio Test
†Multivariable logistic regression model was conducted
Fig. 1Antibiotic resistance profiles of Staphylococcus aureus (n = 171), Enterobacterales (n = 99), and Pseudomonas aeruginosa isolates (n = 46). *n = 119, **n = 157, †n = 81, ‡n = 74, §n = 34. AMK Amikacin, ATM Aztreonam, CAZ Ceftazidime, CIP Ciprofloxacin, CLI Clindamycin, CRO Ceftriaxone, DOX Doxycycline, ERY Erythromycin, ETP Ertapenem, FEP Cefepime, FOS Fosfomycin, FOX Cefoxitin, FUS Fusidic acid, GEN Gentamicin, IPM Imipenem, LNZ: Linezolid, LVX Levofloxacin, MEM Meropenem, MNO Minocycline, PEN Penicillin, SXT Trimethoprim-sulfamethoxazole, TCC Ticarcillin-clavulanic acid, TCY Tetracycline, TEC Teicoplanin, TOB Tobramycin, TZP Piperacillin-tazobactam, VAN Vancomycin